Abivax (ABVX) Total Debt (2021 - 2026)

Abivax's Total Debt history runs 6 years deep, the most recent figure standing at $77.1 million for Q1 2026.

• On a quarterly basis, Total Debt rose 200.82% year-over-year to $77.1 million in Q1 2026; TTM through Mar 2026 was $77.1 million, a 200.82% increase from a year earlier, with the FY2025 full-year figure at $71.0 million, down 42.43% from the prior year.
• Total Debt rose to $77.1 million in Q1 2026 per ABVX's latest filing, from $71.0 million in the prior quarter.
• Across five years, Total Debt topped out at $121.8 million in Q4 2024 and bottomed at $20.2 million in Q4 2022.
• The 5-year median for Total Debt is $71.0 million (2025), against an average of $63.4 million.
• Across the five-year window, Total Debt sank 71.38% in 2022 and surged 200.82% in 2026, its largest moves.
• Year by year, Total Debt stood at $20.2 million in 2022, then surged by 116.71% to $43.7 million in 2023, then surged by 178.81% to $121.8 million in 2024, then slumped by 41.69% to $71.0 million in 2025, then increased by 8.56% to $77.1 million in 2026.
• Per Business Quant, the three latest ABVX Total Debt figures stand at $77.1 million (Q1 2026), $71.0 million (Q4 2025), and $82.0 million (Q3 2025).